PanoramicaGraficoNotizieSchermataTrader

UniCredit Knock-Out NVSEF/  DE000HD532E3  /

EUWAX
13/11/2024  09:22:26 Var.-0.010 Denaro14:26:59 Lettera14:26:59 Sottostante Prezzo di esercizio Expiration date Tipo di opzione
0.370EUR -2.63% 0.350
Quantità in denaro: 70,000		 0.360
Quantità in lettera: 70,000		 Novartis AG 88.5105 - 31/12/2078 Call
TeleTrader 29/10 Novartis' Q2 EPS surge by 116% to $1.58
GlobeNewswire 30/07 Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
TeleTrader 18/07 Novartis Q2 EPS up 47% to $1.60
GlobeNewswire 08/07 Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
GlobeNewswire 26/06 As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire 13/06 Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
GlobeNewswire 29/05 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
GlobeNewswire 13/05 Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
TeleTrader 02/05 Novartis to acquire Mariana Oncology for $1.7B
TeleTrader 23/04 Novartis up 5% on upbeat guidance, earnings
TeleTrader 23/04 Novartis EPS up 28% to $1.31 in Q1
GlobeNewswire 16/04 Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...
GlobeNewswire 11/04 Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Develo...
TeleTrader 11/04 Novartis launches offer for Morphosys at €68 per share
TeleTrader 09/04 Novartis to reduce workforce by 680 in Product Development
GlobeNewswire 14/03 IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
TeleTrader 12/03 Germany clears Novartis' MorphoSys $2.9B deal
GlobeNewswire 28/02 Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire 28/02 PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invas...
TeleTrader 05/02 Novartis to acquire MorphoSys for $2.9B
TeleTrader 31/01 Novartis net sales up 8% to $11.4B in Q4
GlobeNewswire 10/01 Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...
GlobeNewswire 05/01 Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...
GlobeNewswire 02/01 Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...
GlobeNewswire 21/12/2023 Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...